Tempus secured a distribution agreement with Predicta Biosciences to expand access to its whole-genome sequencing (WGS)-based GenoPredicta assay for multiple myeloma. The test is designed to identify actionable DNA alterations in blood or bone marrow and to support risk stratification. Tempus says GenoPredicta can be used to evaluate high-risk multiple myeloma and to monitor minimal residual disease, positioning WGS as a unified workflow that replaces multiple siloed assays. The company claims assay sensitivity from small tumor inputs, supporting clinical utility where disease burden may be limited. For precision oncology operations, this agreement signals continued movement toward comprehensive genomic profiling strategies and away from piecemeal testing architectures. It also adds depth to Tempus’s laboratory and informatics ecosystem, reinforcing its role in connecting molecular data to decision-making. While financial terms were not disclosed, the deal is likely to affect payer discussions and lab adoption decisions as WGS assays compete on interpretability, turnaround time, and evidence for clinical outcomes tied to assay outputs.